CRIS Current Research Information System

NANNI, JACOPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.430
NA - Nord America 1.545
EU - Europa 1.271
AF - Africa 164
SA - Sud America 110
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.528
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.515
VN - Vietnam 638
SG - Singapore 613
CN - Cina 591
IT - Italia 463
HK - Hong Kong 188
GB - Regno Unito 145
KR - Corea 129
DE - Germania 118
SE - Svezia 106
NL - Olanda 98
IN - India 81
BR - Brasile 76
FR - Francia 65
FI - Finlandia 58
CI - Costa d'Avorio 45
RU - Federazione Russa 45
JP - Giappone 42
IE - Irlanda 41
SC - Seychelles 33
ZA - Sudafrica 28
TG - Togo 26
JO - Giordania 19
BG - Bulgaria 18
ID - Indonesia 18
ES - Italia 17
AT - Austria 16
NG - Nigeria 16
PH - Filippine 16
PL - Polonia 16
CA - Canada 15
TR - Turchia 15
TH - Thailandia 13
TW - Taiwan 12
BD - Bangladesh 10
CH - Svizzera 10
EC - Ecuador 10
MX - Messico 10
AR - Argentina 9
BE - Belgio 9
IQ - Iraq 9
UA - Ucraina 8
EE - Estonia 7
AU - Australia 6
GR - Grecia 6
IR - Iran 6
LT - Lituania 6
PK - Pakistan 6
UZ - Uzbekistan 6
AL - Albania 4
CL - Cile 4
MA - Marocco 4
PY - Paraguay 4
TN - Tunisia 4
EG - Egitto 3
HR - Croazia 3
UY - Uruguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CY - Cipro 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
KW - Kuwait 2
KZ - Kazakistan 2
MK - Macedonia 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AM - Armenia 1
CO - Colombia 1
DZ - Algeria 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.528
Salva come PNG Salva come JPEG
Città #
Singapore 455
Ashburn 211
Hefei 209
Ho Chi Minh City 177
Hong Kong 162
Hanoi 144
Chandler 127
Seoul 118
San Jose 113
Southend 109
Bologna 104
Dallas 93
Milan 59
Ann Arbor 54
Fairfield 50
Santa Clara 50
Beijing 49
Helsinki 46
Abidjan 45
New York 45
Dublin 41
Los Angeles 37
Boardman 35
Tokyo 34
Princeton 30
Haiphong 28
Lauterbourg 26
Lomé 26
Houston 22
Frankfurt am Main 21
Wilmington 21
Bengaluru 20
Da Nang 20
Seattle 20
Amman 19
Council Bluffs 19
Cambridge 18
Johannesburg 18
Sofia 18
Amsterdam 17
Rome 16
Redondo Beach 15
Abeokuta 14
Nanjing 14
Turin 14
Woodbridge 14
Biên Hòa 13
Buffalo 13
Guangzhou 13
Jakarta 13
Falkenstein 12
Florence 12
Redmond 12
Hải Dương 11
Vienna 11
Bremen 10
Castel Maggiore 10
Munich 10
Nuremberg 10
Shanghai 10
Tianjin 10
Warsaw 10
Phoenix 9
Brussels 8
Can Tho 8
London 8
Modena 8
Orem 8
Orlando 8
São Paulo 8
Zhengzhou 8
Atlanta 7
Bắc Ninh 7
Chicago 7
Medford 7
Paris 7
Toronto 7
Westminster 7
Bangkok 6
Berlin 6
Catania 6
Chengdu 6
Lappeenranta 6
Madrid 6
Ninh Bình 6
Padova 6
Quận Bình Thạnh 6
Reggio Emilia 6
San Diego 6
Tongling 6
Brooklyn 5
Forlì 5
Hyderabad 5
Irvine 5
Kolkata 5
Mannheim 5
Montreal 5
Nanchang 5
Piscataway 5
Quito 5
Totale 3.421
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 275
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 250
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 229
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 225
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 223
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 202
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 200
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 198
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 198
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 197
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 189
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 188
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 181
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 178
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 176
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 173
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 166
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 166
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 166
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 163
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 161
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 159
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 150
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 149
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 144
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 123
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 121
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 113
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 111
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 100
Editorial: Precision medicine for acute myeloid leukemia 93
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study 64
Acute myeloid leukemia mutations: Therapeutic implications 51
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia 44
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort 41
IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease 40
Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT 39
A clinical experience with CAR-T cell therapy brexu-cel as salvage option for a Relapsed/Refractory patient with B-Cell Acute Lymphoblastic Leukemia in advanced disease stage.|Esperienza con CAR-T brexu-cel in paziente affetto da leucemia linfoblastica acuta B in fase avanzata di ricaduta/refrattarietà 3
Totale 5.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.508
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.508
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 3 11 19
2021/2022382 9 7 10 27 29 17 10 50 20 42 98 63
2022/2023606 58 79 23 57 68 49 14 46 108 12 53 39
2023/2024277 8 25 14 34 20 52 11 28 17 22 33 13
2024/20251.061 45 149 72 76 69 49 116 55 24 114 91 201
2025/20262.959 361 455 234 275 193 138 328 101 676 198 0 0
Totale 5.649